Vitamin K₂—a neglected player in cardiovascular health: a narrative review

Essa Hariri,1 Nicholas Kassis,1 Jean-Pierre Iskandar,1 Leon J Schurgers,2 Anas Saad,3 Omar Abdelfattah,3,4 Agam Bansal,1 Toshiaki Isogai,3 Serge C Harb,1,4 Samir Kapadia3

ABSTRACT

Vitamin K₂ serves an important role in cardiovascular health through regulation of calcium homeostasis. Its effects on the cardiovascular system are mediated through activation of the anti-calcific protein known as matrix Gla protein. In its inactive form, this protein is associated with various markers of cardiovascular disease including increased arterial stiffness, vascular and valvular calcification, insulin resistance and heart failure indices which ultimately increase cardiovascular mortality. Supplementation of vitamin K₂ has been strongly associated with improved cardiovascular outcomes through its modification of systemic calcification and arterial stiffness. Although its direct effects on delaying the progression of vascular and valvular calcification is currently the subject of multiple randomised clinical trials, prior reports suggest potential improved survival among cardiac patients with vitamin K₂ supplementation. Strengthened by its affordability and Food and Drug Administration (FDA)-proven safety, vitamin K₂ supplementation is a viable and promising option to improve cardiovascular outcomes.

INTRODUCTION

Vitamin K is a fat-soluble vitamin that is comprised of multiple similarly structured compounds. Naturally, vitamin K occurs as two vitamers, namely vitamin K₁ (phylloquinone) and vitamin K₂ (menaquinones; MKs). Vitamin K₂ specifically has been highlighted for its long half-life and extrahepatic activity. As such, vitamin K₂ plays a pivotal role in the activation of extrahepatic γ-carboxyglutamate (Gla) proteins such as matrix Gla protein (MGP), a small 84-amino acid (14 kDa) protein that is commonly considered the strongest inhibitor of vascular calcification.1 Primarily synthesised by vascular smooth muscle cells (VSMCs), MGP undergoes two forms of post-translational modifications for complete maturation: γ-glutamate carboxylation and serine phosphorylation, the former of which is vitamin-K dependent.2 During states of vitamin K deficiency, MGP remains uncarboxylated and its biological function is impaired.1 There are several forms of MGP depending on the phosphorylation and carboxylation status. The circulating inactive unphosphorylated and uncarboxylated form of MGP (dp-ucMGP) is an established biomarker for vitamin K deficiency.3 4 The use of vitamin K antagonists (VKAs) such as warfarin can induce a deficiency in MGP, which may contribute to the formation and evolution of vascular calcification, an independent predictor of cardiovascular morbidity and mortality.5

In light of expanding preclinical and clinical data on the cardiovascular benefits of vitamin K₂ with multiple ongoing clinical trials investigating its role in various outcomes, there is a pressing need to organise our understanding of the pathophysiology, safety, and efficacy of vitamin K₂ intake as it relates to markers and outcomes of cardiovascular health. The aim of this comprehensive narrative review, divided into two major sections, is to summarise the literature for scientists...
and clinicians on: (1) the role of MGP in cardiovascular health, and (2) the cardiovascular benefits of vitamin K₂ dietary intake and supplementation. We will first discuss the pathophysiological interplay between vitamin K₂ and MGP. By providing an organised framework of the available evidence, we will then elucidate the association of vitamin K deficiency and MGP on the various markers of cardiovascular health. In the second section, this review will outline the clinical impact of dietary and supplemental vitamin K₂ intake on these outcomes, citing the data of its use as a novel and practical addition to our arsenal of cardioprotective therapies.

VITAMIN K-DEPENDENT PROTEINS AND CARDIOVASCULAR HEALTH

Role of MGP in cardiovascular health

There is a growing body of evidence supporting the vital role of MGP in cardiovascular disease (CVD). This was first demonstrated in MGP knock-out mice who suffered premature death within 6–8 weeks after birth consequent to massive arterial calcification and spontaneous aortic rupture. A paradigm shift around vascular calcification has since emerged whereby the previous notion of a passive, degenerative, and irreversible process is presently understood as an actively regulated and tenably preventable or reversible mechanism.

Figure 1 depicts the mechanism by which vitamin K₂ regulates systemic calcification through activation of MGP in VSMCs and chondrocytes. After the transcription and translation of MGP into dp-ucMGP, it undergoes post-translational modification through two distinct processes: (1) kinase-mediated serine phosphorylation, and (2) γ-carboxylation of glutamic acid residues mediated by γ-carboxylase, which requires vitamin K as a cofactor. The latter process is akin to the activation of several other vitamin-K dependent proteins such as coagulation factors. The resultant active form of MGP, an 84-amino acid (approximately 14 kDa) protein, is thought to protect against soft tissue calcification via several processes. Calcium apatite is the predominant form of calcium crystals that accumulate in blood vessel walls, and it is also commonly found in bone. Notably, the process of vascular calcification resembles bone formation as matrix vesicles bud from cells and form a nidus for calcification. In vivo studies have shown that in the absence of activated MGP, VSMCs differentiate into cells with properties of chondrocytes and osteoblasts, producing a matrix that favours calcium crystal deposition. MGP regulates calcification directly by inhibiting formation and solubilisation of calcium crystals and through alternative calcification inhibitors such as fetuin-A, as well as indirectly via modulating transcription factors that suppress differentiation of VSMC to an osteoblast-like phenotype. Moreover, research demonstrates that only the active, carboxylated form of MGP antagonises the action of pro-calcific proteins; for instance, it inhibits bone morphogenic protein-2 (BMP-2), a potent pro-osteoblastic protein heavily expressed in atherosclerotic lesions in states of inflammation and oxidative stress, which induces an osteogenic gene expression profile in VSMC.

Role of other vitamin K-dependent proteins in cardiovascular health

It is important to note that there other vitamin K-dependent proteins implicated in cardiovascular health, including bone Gla protein (or osteocalcin (OC)) and Gas6 (growth arrest-specific 6) protein. The role of OC in cardiovascular health is manifested by modulation of vascular calcification through activation of adiponectin, a protein that has been shown to inhibit osteoblastic differentiation of VSMCs. Moreover, OC has been shown to reduce arterial stiffness in diabetic rat model. These findings have been replicated in human studies, as OC has been shown to be associated with adiponectin in patients with chronic kidney disease (CKD). A study by Fusaro et al found lower OC levels in
patients with aortic and iliac calcifications as compared with patients without calcifications. Moreover, in a prospective study of 774 men aged 51–83 years from the MINOS cohort who had OC measured at baseline and were followed over 10 years with serial measurements of abdominal aortic calcification, higher baseline total OC was associated with a lower abdominal aortic calcification progression rate (OR=0.74 (0.57 to 0.97) per 10 ng/mL variation; p=0.029) and lower 10-year all-cause mortality (HR=0.62 (0.44 to 0.86) per 10 ng/mL variation; p=0.005). In light of the above studies, a meta-analysis of 46 studies showed no definitive association of OC with vascular calcification; it is important to mention, however, the considerable variability in adjustment for confounders, heterogeneity of the populations and assays used for measurement of serum OC in these studies.

Besides, Gas6 protein is a vitamin K-dependent protein that highly expressed in lungs, hearts and kidneys and has been shown to regulate calcification of VSMCs. It has also been shown that androgen receptor signaling inhibits vascular calcification through enhanced Gas6 transcription. Similar findings have been shown with adiponectin and its effect on vascular calcification through alterations in Galectin expression. Alternatively, Gas6 is also known to protect against endothelial dysfunction and VSMC apoptosis, both of which are mechanisms that mediate vascular calcification. Moreover, in vitro data revealed that phosphate-induced calcification of VSMC is associated with a downregulation of Gas6 expression.

**Measurement of vitamin K$_2$ levels**

In order to investigate the role of vitamin K$_2$ on cardiovascular health, a biomarker reflecting vitamin K status is required. This has been achieved by assessing the status of vitamin K$_2$-dependent proteins that require carboxylation, and assays measuring MGP seem to be the most commonly used ones, a measurement that reflects the bioactivity of vitamin K over a span of weeks to months. The assay that quantifies vitamin K deficiency seems to extend beyond protection from calcification and is implicated in reduced elastin degradation and collagen formation in the arterial wall, both of which can potentially improve arterial stiffness.

**Coronary and vascular calcification**

It is well established that MGP inhibits vascular calcification. This was first reported in human Keutel syndrome, which is characterised by systemic vascular calcification due to loss-of-function mutations in the MGP gene. Studies have shown that MGP inhibition of ‘pro-osteoblastic’ transcription factor BMP-2 relies on carboxylation. Moreover, warfarin, a VKA, has been shown to accelerate coronary, aortic valvular and mitral annular calcification (MAC). Genetic studies have also linked polymorphism in the gene encoding MGP with vascular calcification and coronary artery disease (CAD). The relationship between low vitamin K status and systemic calcification in humans has been described in several studies done on several patient populations. Dalmeijer et al found a greater trend of coronary artery calcification (CAG) in postmenopausal women with higher plasma dp-ucMGP, and Llaubères et al showed a significant association between dp-ucMGP and peripheral arterial calcification score. More recently, there are data to suggest that dp-ucMGP may be associated with higher plaque stability; in a study on 100 patients undergoing carotid endarterectomy and histological evaluation of the carotid plaque, elevated dp-ucMGP was associated with less plaque haemorrhage, suggesting more plaque stability.

**Valvular calcification**

Aortic stenosis (AS) is commonly described as a degenerative disease characterised by progressive aortic valve calcification with no effective medical therapy to delay its progression available to date. Retrospective work has linked warfarin use to increased aortic and mitral valve calcification in humans, and observational data suggest that warfarin is significantly associated with structural and haemodynamic progression of AS. Besides, a multi-centre observation study on patients with CKD stages 3b–4 and non-valvular atrial fibrillation receiving either warfarin (n=100) or rivaroxaban (n=247) was conducted between 2015 and 2017 to assess their differential impact on valvular calcification measured by echocardiography. The study showed that rivaroxaban reduced both mitral and aortic calcification compared with warfarin (p<0.001) irrespective of baseline calcification and confounding factors.
Both MAC and AS are associated with cardiovascular morbidity and mortality as well as with calcium deposition in the aorta and various arterial beds, which may be localised sequelae of a systemic disease of dysregulated calcium metabolism.42 Previously described as passive degeneration, progression of valvular calcification has recently been identified as an active, potentially modifiable process. A cross-sectional study of 839 community patients with stable CAD found a strong association between serum inactive total MGP and MAC in those without diabetes, irrespective of age, renal function, albumin, C reactive protein (CRP) and traditional CVD risk factors. This association persisted after adjusting for calcium, phosphorus and fetuin-A levels.43 Moreover, polymorphism in MGP gene has been implicated in progression of aortic calcification in a randomly selected general population of 296 individuals who participated in the European Vertebral Osteoporosis Study.44

Measuring inactive forms of MGP, reflecting vitamin K deficiency, may ultimately prove useful in identifying individuals at increased risk of cardiac valve disease progression, and by extension, persons at greater risk of heart failure (HF) and CVD events. Elucidating the mechanisms behind valvular calcification may therefore offer novel insights into CVD.

Microvascular function
The benefits of MGP may also extend to microcirculation of various tissues. MGP is abundantly expressed in tissues of the retina,45 kidneys46 and the heart,47 and is postulated to contribute to microvascular integrity of these organs through anti-calcific and anti-stiffness properties. In a community study done on 935 randomly recruited Flemish participants (mean age, 40.9 years; 50.3% women) and followed over a median of 11 years, higher dp-ucMGP was associated with a decrease of retinal arteriolar diameter,48 which is a prognostic marker of cardiovascular outcomes.49

Chronic kidney disease
Markers of vitamin K deficiency have been shown to be associated with indices of adiposity and inflammation as well as diabetes and kidney function.12 50 In one randomised clinical trial, poor vitamin K status as deduced from low plasma levels of carboxylated OC (cOC) was associated with a higher fat mass at different body sites and with waist circumference, while high vitamin K levels as deduced from high cOC levels were inversely associated with high-sensitivity CRP, leptin and insulin.51

Vitamin K deficiency, whether measured through phylloquinone (via uOC assay) or MKs (via dp-ucMGP assays), is very prevalent in patients with CKD with more than 60% having some form of vitamin K deficiency.12 Specifically, functional vitamin K deficiency is also prevalent among haemodialysis and renal transplant recipients52 and may, in part, account for their reduced vitamin K function and increased subsequent risk of vascular calcification.52 53 Despite improvement in vitamin K levels following kidney transplantation, vitamin K deficiency as assessed by dp-ucMGP in kidney transplant patients was associated with significantly increased risk in all-cause mortality (HR=3.10; 95% CI: 1.87 to 5.12) among 518 patients with renal transplant followed over a median follow-up of 9.8 years.54

In regard to renal function, circulating inactive dp-ucMGP was associated with progression to renal dysfunction, as assessed by reduction in glomerular filtration rate (GFR) and presence of microalbuminuria, in a study on 1009 Flemish subjects who were followed for a median of 8.9 years.55 To substantiate these findings, the same investigators studied the histological findings of kidney biopsies from two healthy kidney donors and four patients with renal dysfunction.56 They found that tissues from diseased kidneys but not from healthy kidneys stained positive for calcium deposits and both carboxylated and uncarboxylated MGP, suggesting a potential role of MGP in renal tissue calcification beyond just vascular calcification. Another cross-sectional analyses of 1166 white Flemish and 352 black South Africans supported these findings as higher dp-ucMGP was associated with lower estimated GFR (p≤0.023), and subsequent greater risk of developing more advanced CKD.57

Besides, patients with end-stage renal disease requiring haemodialysis are severely vitamin K deficient as evidenced by higher total MGP.3 One analysis from the Vitamin K Italian (VIKI) dialysis study including 387 patients on haemodialysis shows that vitamin K deficiency, measured by MK-4 and MK-7 serum levels, is significantly associated with aortic and iliac arterial calcification (OR=2.82 and 1.61, respectively; p<0.05).58 Another study of 842 patients with stable coronary disease in the community setting demonstrated a direct association between GFR and serum levels of inactive, ucMGP after adjusting for confounders.59 Further, MGP has been correlated with serum creatinine in those with HF and CKD.60 61 In a separate study by Kurnatowska et al that investigated 38 non-dialysed Caucasian non-smokers aged 18–70 years with CKD stages 4–5 who were supplemented with vitamin K\textsubscript{\textit{\textalpha}}, plasma dp-ucMGP was positively associated with proteinuria, serum creatinine, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23), and inversely associated with GFR.62

Cardiac microcirculation
From the perspective of cardiac microcirculation, Paulus and Tschöpe proposed a novel theory surrounding left ventricular (LV) diastolic dysfunction that shifted emphasis from LV afterload to inflammation of the coronary microcirculation,62 ultimately implicating MGP in the disease process. In one study of over 900 Flemish and Swiss patients, dp-ucMGP correlated with diastolic dysfunction as assessed by increased LV filling pressures and higher \(E/e'\) ratio.63 In this study, cardiac biopsies of ischaemic or dilated cardiomyopathy and healthy hearts (\(n=4\) for each) were stained with conformation-specific MGP antibodies. The authors found a higher prevalence
of uncarboxylated inactive, dp-ucMGP in the perivascular matrix and interstitium of diseased relative to normal hearts (p≤0.004), concluding that activated MGP is an ubiquitous, locally acting molecule that protects the microcirculation and perivascular matrix from injury caused by calcium deposition by sequestering intracellular calcium, thereby preserving LV diastolic function.

**HF measures and mortality**

Patients with symptomatic AS frequently develop LV outflow obstruction and LV hypertrophy as a compensatory mechanism to maintain the ejection performance. In light of the dramatic increase in mortality rate after symptom onset, aortic valve replacement is recommended in symptomatic patients with AS.

It is well founded that circulating dp-ucMGP levels play a role in both systolic and diastolic cardiac function and their associated effects on mortality. In two Norwegian studies, significant associations were found between higher plasma dp-ucMGP and unfavourable echocardiographic measures and mortality among patients with severe AS and chronic heart (HF). Among 147 patients with symptomatic AS, dp-ucMGP was significantly higher in diseased patients compared with healthy sex-matched and age-matched controls. Moreover, levels of dp-ucMGP were significantly correlated with neurohumoral (N-terminal pro-brain natriuretic peptide (NT-proBNP)) and haemodynamic markers (LV ejection fraction and cardiac index) of HF severity in non-warfarin users, and with NT-proBNP in warfarin users. Importantly, higher dp-ucMGP concentration correlated with all-cause mortality (HR ~7) after a mean follow-up of 23 months suggesting that a dysregulated MGP system may play a role in the development of LV hypertrophy and HF mortality in these patients. Moreover in this study, the risk of mortality was highest in patients who underwent aortic valve replacement. This confers a tenable role for dp-ucMGP not only in untreated patients with symptomatic AS, but additionally as a pre-procedural marker for long-term risk evaluation in patients who undergo aortic valve replacement. The second study found that among 179 patients with chronic systolic and diastolic HF, increased dp-ucMGP was associated with greater disease severity compared with healthy age-matched and sex-matched controls. Elevated dp-ucMGP further correlated with increased CRP, NT-proBNP, systolic (LV ejection fraction) and diastolic dysfunction, and ischaemia as the aetiology for HF. After a mean 2.9 years, patients in the highest tertial of dp-ucMGP level had increased all-cause mortality, and dp-ucMGP was markedly higher in those who died due to HF progression.

From a pathophysiological perspective, the MGP system may serve both direct and indirect roles in the cellular processes associated with myocardial remodelling and the development and progression of HF. The absence of myocardial calcification in MGP-deficient mice implies possible interplay between MGP and cardiac haemodynamics unrelated to inhibition of calcification. Elevated MGP levels are seen during rapid myocardial response to pressure overload, potentially induced by angiotensin II, suggesting a relationship between neurohumoral maladaptive responses and MGP. Prior DNA microarray animal and human studies have demonstrated increased mRNA expression of MGP in the LV during acute and chronic pressure overload and in experimental HF in rats and mice. Moreover, studies have demonstrated that MGP anchors to the extracellular matrix by binding to vitronectin, which may have modifying effects on members of the transforming growth factor β family that influence cardiac remodelling during HF. Most recently, Mustonen et al showed that following a myocardial infarction, MGP is rapidly upregulated in response to cardiac overload long before the development of LV hypertrophy and remodelling. While the precise mechanism remains unclear, there is increasing plausibility that plasma dp-ucMGP and valvular calcification are vital in cardiac dysfunction among patients with AS.

**Cardiovascular morbidity and mortality**

Accumulating evidence highlights a relationship between a low state of circulating vitamin K, signified by elevated dp-ucMGP, and the development and progression of CVD and mortality. Studies from Norway and Czech Republic demonstrate a strong association between higher plasma dp-ucMGP and risk of all-cause mortality. Notably, two Mendelian randomisation studies found that lower genetically predicted dp-ucMGP was causally associated with cardiovascular risk and mortality.

A prospective study over a mean 5.6 years in an elderly population found that high plasma dp-ucMGP concentrations correlated with an increased risk of incident CVD, defined as one or more of coronary heart disease, peripheral arterial disease and CAD, independent of traditional cardiac risk factors and vitamin D status. Another investigation showed that elevated dp-ucMGP was associated with an increased hazard of incident CVD (CAD, peripheral artery disease, HF and stroke) after a median follow-up of 11.2 years among 518 patients with type 2 diabetes. Additionally, Mayer et al found that among 799 patients with past myocardial infarction, coronary revascularisation, or first ischaemic stroke, increased plasma dp-ucMGP conferred an elevated risk of both all-cause and cardiovascular mortality at 5 years, despite adjusting for potential confounders. In a subsequent subcohort analysis of patients with HF within this population, high dp-ucMGP was associated with 5-year all-cause mortality, with the largest HR found among those with elevated BNP (>100 ng/L). More recently, the role of dp-ucMGP on cardiovascular outcomes was studied in 894 patients with ischaemic heart disease (at least 6 months after they had myocardial infarction and/or coronary revascularisation); high dp-ucMGP was significantly associated with 2.4 and 3.5 higher risk of 5-year all-cause and cardiovascular mortality, respectively.
These studies stand in contrast with a prospective case–cohort investigation from the European Prospective Investigation Into Cancer and Nutrition–Netherlands (EPIC-NL) Study which failed to reveal an association between high dp-ucMGP and increased CVD or stroke after a mean 11.5 years.⁷⁸ Similarly, in the Health ABC Study where plasma vitamin K₃ (phylloquinone) and dp-ucMGP were measured in 1061 participants free of CVD (aged 70–79 years) who are followed for over 12 years, the authors did not show an association with either markers of vitamin K and incident CVD; however, in a subset of subjects with treated hypertension, low plasma phylloquinone was associated with higher CVD risk overall (HR= 2.94; 95% CI: 1.41 to 6.13).⁷⁶ Notwithstanding, a recent meta-analysis aimed in assessing the prospective association between vitamin K₃ and CVD and all-cause mortality importantly identified a relationship between elevated plasma dp-ucMGP and all-cause mortality (pooled HR=1.84, 95% CI: 1.48 to 2.28; five studies) and cardiovascular mortality (pooled HR=1.96, 95% CI: 1.47 to 2.61; two studies).⁶

It remains evident that vitamin K deficiency is strongly associated with several markers of cardiovascular health, and plasma MGP represents a clinically feasible and sensitive tool to assess for such deficiency. Moreover, measuring inactive MGP is a powerful biomarker that can be incorporated in clinical and translational research, particularly for investigating calcification, HF and arterial stiffness. Whether intake of vitamin K₃ through supplementation or diet has the potential to reduce the risk of such cardiovascular outcomes will be further discussed in the next sections.

Vitamin K₂ and cardiovascular health

The literature surrounding vitamin K₂ dates to its discovery in the 1930s and identification of its molecular mechanisms in the 1970s,⁷² and continues to grow after the recent discovery of the role of active MGP on vitamin K-dependent vascular calcification. Notwithstanding the breadth of research, an organised and succinct understanding of its cardiovascular role remains limited. The following sections provide a comprehensive but concise overview of the evidence related to the cardiovascular benefits of vitamin K₂ intake through diet and supplementation.

Dietary intake

Vitamin K is a fat-soluble vitamin found in two forms: (1) phylloquinones (vitamin K₃), present in leafy green vegetables and responsible for mediating coagulation, and (2) MKs (vitamin K₃), present in fermented food and implicated in systemic calcification.⁷⁶ Its pattern of bodily distribution appears tissue specific.⁷⁹ While vitamin K₃ concentrates in the liver where it regulates the production of coagulation factors, vitamin K₂ is found in extrahepatic tissues such as bones and arteries.⁸₂ Long-chain MKs (ie, MK-7) are transported more efficiently to extrahepatic tissues.⁸⁰ Intake of vitamin K₂ through diet alone is seemingly inadequate for complete activation of MGP in humans.⁸¹ MK-7 is in relatively low abundance in Western diets as it is commonly found in a variety of fermented foods such as natto and, to a much lesser extent, meats and dairy products.⁷⁸ ⁸² Among a subcohort of 4275 subjects from the Prevention of Renal and Vascular End-stage Disease (PREVEND) Study, 31% had functional vitamin K insufficiency (ie, dp-ucMGP >500 pmol/L).³³ Children and those over 40 years of age are mostly vitamin K deficient as measured by dp-ucMGP.⁸⁴ Human studies have shown that high vitamin K₂ intake is associated with reduced coronary artery calcification and CVD risk, and those effects are thought to be mediated by increased activation of MGP.⁸⁵–⁸⁷ For example, intake of natto, which is a vitamin K₂-rich food common in the Japanese population, has been shown to be associated with lower hazard of CVD mortality (HR=0.75, p trend=0.0004) in a large Japanese cohort study of 13 355 men and 15 724 women, followed over 16 years.⁸⁸

Oral supplementation

The effective recommended dose of longer chain MKs (MK-7, MK-8 and MK-9) for cardiovascular health benefits is 180–360 µg/day.⁸⁹–⁹⁰ Epidemiological evidence suggests that intake of vitamin K₃ and K₂ reduces cardiovascular and overall mortality.⁹¹ A substantial portion of ingested vitamin K₉ is converted into K₂, which in turn accumulates within the extrahepatic tissues. Studies of vitamin K₂ supplementation used markedly higher doses (1–2 mg/day) than vitamin K₉, especially MK-7 (180–360 µg/day), most likely due to the predominant extrahepatic activity and vascular tissue specificity of vitamin K₂ relative to K₉. Both isotypes are potentially comparable in their overall health effects, yet the higher vascular-specific activity of vitamin K₉ may make it increasingly appealing as an efficacious option for utilisation in cardiovascular outcomes studies. Supplementing vitamin K₉ is also promising in its ability to replete plasma stores of vitamin K₂ and ultimately sustain an optimal level for inhibiting calcification. Supplementation has previously been associated with a dose-dependent reduction in circulating dp-ucMGP,⁹² ⁹³ and an ensuing improvement in arterial stiffness among healthy adults and those with end-stage renal disease requiring haemodialysis.⁹⁴ ⁹⁵ In a supplementary analysis, MK-7 was well tolerated in failing to cause a hypercoagulable state.⁹⁶ There have been no documented cases of toxicity of vitamin K₂, MK-4 or MK-7. Additionally, the WHO has set no upper tolerance level for vitamin K intake.⁹⁷

Cardiovascular risk factors

The following sections will discuss the influence of vitamin K specifically focusing on vitamin K₂, on various cardiovascular risk factors, including arterial stiffness, endothelial dysfunction, cardiac output, diabetes mellitus, valvular and vascular calcification, and cardiovascular mortality.
In light of such evidence, vitamin K2 has been strongly associated with arterial calcification, cardiac systolic and diastolic functions, mortality, including arterial stiffness, valvular calcification, surrogate measures of cardiovascular morbidity and mortality, with improved cardiovascular health by improving arterial, endothelial and myocardial function and with potential for improved overall survival.

Vitamin K2 has been shown to have strong potential in reducing several surrogate measures of cardiovascular morbidity and mortality, including arterial stiffness, valvular calcification, arterial calcification, cardiac systolic and diastolic functions. In light of such evidence, vitamin K2 has been strongly associated with improved cardiovascular health by improving arterial, endothelial and myocardial function and with potential for improved overall survival.

Vitamin K2 supplementation may also potentially target vascular calcification. Vitamin K2 supplementation may delay the progression of aortic valve calcification. In a rat model, warfarin-induced arterial calcification and arterial stiffness, where inactive MGP was highly expressed, appeared to regress with a diet rich in vitamin K. Additional studies have demonstrated that 4 weeks of supplementing 30 mg/day of vitamin K2 (menatetrenone) significantly increased the insulin sensitivity index (p<0.01) compared with placebo in healthy young men. The benefits of vitamin K2 extend beyond direct effect on type 2 diabetes as it has been recently shown in a randomised placebo-controlled trial on 214 postmenopausal healthy women receiving 180 µg/day of vitamin K2 (MK-7) or placebo, to have favourable effect on obesity with reduction in abdominal and visceral fat among those who responded well to MK-7 (manifested through elevated of cOC).

Vascular and valvular calcification

Anticoagulation-mediated inhibition of vitamin K metabolism has been associated with progression of both vascular and valvular calcification. Animal studies have found increased arterial and soft tissue calcification as a result of inhibition of vitamin K-dependent proteins by VKA. Long-term VKA use is associated with both coronary and extracoronary vascular calcification in humans. Sønderskov et al recently demonstrated that among 14,604 participants within the Danish Cardiovascular Screening (DANCAVAS) trial, VKA use was associated with progression of aortic valve calcification, evidenced by a 6% increase in calcification with each year of treatment. These results remained consistent after a sensitivity analysis excluding patients with cardiac risk factors on statins showed no progression of calcification in those taking direct oral anticoagulants.

Vitamin K supplementation may delay the progression of aortic valve calcification. In a rat model, warfarin-induced arterial calcification and arterial stiffness, where inactive MGP was highly expressed, appeared to regress with a diet rich in vitamin K. The first in-human randomised control trial recently found that among a small cohort of 99 patients with AS, vitamin K2 intake (2 mg daily) decelerated the progression of CT-based aortic valve calcification compared with placebo (10% vs 22%, respectively; p=0.04). It is important to note that 27 patients (12 vitamin K2, 15 placebo) dropped out of the study.

Vitamin K2 supplementation may also potentially target vascular calcification. Vitamin K2 intake has been associated with increased cardiac output, stroke volume and heart rate, and decreased blood lactate. These effects are consistent with the greater maximal cardiovascular performance seen with oral vitamin K2 supplementation.
### Table 1  Role of vitamin K on markers of CVD

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Patient population</th>
<th>Study methods</th>
<th>Study findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arterial stiffness</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Braam et al&lt;sup&gt;84&lt;/sup&gt;</td>
<td>181</td>
<td>Healthy postmenopausal Caucasians between 50 and 60 years of age</td>
<td>Design: double-blind RCT</td>
<td>↑Distensibility (+8.8%, p&lt;0.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex: female only</td>
<td>Intervention: vitamin D&lt;sub&gt;3&lt;/sub&gt; (8 µg) + K&lt;sub&gt;1&lt;/sub&gt; (1 mg) supplementation</td>
<td>↑Compliance (+8.6%, p&lt;0.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age: 55</td>
<td>Follow-up (years): 3</td>
<td>↓Pulse pressure (−6.3%, p&lt;0.05)</td>
</tr>
<tr>
<td>Knapen et al&lt;sup&gt;95&lt;/sup&gt;</td>
<td>244</td>
<td>Healthy, postmenopausal subjects aged 55–65 years</td>
<td>Design: double-blind RCT</td>
<td>↓Carotid–femoral PW</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex: female only</td>
<td>Intervention: vitamin K&lt;sub&gt;2&lt;/sub&gt; (MK-7) supplementation (180 µg)</td>
<td>↓Stiffness Index β (p&lt;0.02)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age: 60</td>
<td>Follow-up (years): 3</td>
<td></td>
</tr>
<tr>
<td>Ikari et al&lt;sup&gt;96&lt;/sup&gt;</td>
<td>26</td>
<td>Patients with coronary calcification and at least 1 coronary risk factor</td>
<td>Design: open-label, single arm</td>
<td>↓Brachial–ankle PW by 18%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex: 65% female</td>
<td>Intervention: vitamin K&lt;sub&gt;2&lt;/sub&gt; (MK-4) supplementation (45 mg)</td>
<td>only in patients with vitamin K&lt;sub&gt;2&lt;/sub&gt; deficiency (p=0.03)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age: 69</td>
<td>Follow-up (years): 1</td>
<td></td>
</tr>
<tr>
<td>Mansour et al&lt;sup&gt;97&lt;/sup&gt;</td>
<td>60</td>
<td>Adult renal transplant recipients with functioning graft for ≥3 months</td>
<td>Design: prospective, single-</td>
<td>↓Mean carotid–femoral PW by 14.2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex: 43% female</td>
<td>centre, single-arm trial</td>
<td>(p&lt;0.001)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age: 50</td>
<td>Intervention: vitamin K&lt;sub&gt;2&lt;/sub&gt; (MK-7) supplementation (360 µg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Follow-up (weeks): 8</td>
<td></td>
</tr>
<tr>
<td>Vermeer and Hogne&lt;sup&gt;95&lt;/sup&gt;</td>
<td>243</td>
<td>Healthy adults without a history of cardiovascular disease</td>
<td>Design: double-blind, placebo-</td>
<td>↑Mean carotid–femoral PW in placebo group (p&lt;0.005) but no significant change in MK-7 group</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex: 54%</td>
<td>controlled RCT</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age: 61</td>
<td>Intervention: vitamin K&lt;sub&gt;2&lt;/sub&gt; (MK-7) supplementation (180 µg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Follow-up (years): 1</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac output</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McFarlin et al&lt;sup&gt;98&lt;/sup&gt;</td>
<td>26</td>
<td>Aerobically trained athletes with normal body composition</td>
<td>Design: double-blind RCT</td>
<td>↑Maximal cardiac output by 12%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex: 31% male</td>
<td>Intervention: vitamin K&lt;sub&gt;2&lt;/sub&gt; supplementation (300 mg for 4 weeks, then 150 mg for 4 weeks)</td>
<td>(p=0.03)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age: 21</td>
<td>Follow-up (weeks): 8</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolic syndrome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beulens et al&lt;sup&gt;99&lt;/sup&gt;</td>
<td>38 094</td>
<td>Dutch subjects without diabetes aged 20–70 years from the Prospect-EPIC and MORGEN-EPIC cohorts (1993–1997)</td>
<td>Design: prospective, population-based cohort study</td>
<td>↓Risk of incident type 2 diabetes with 10 µg increment increase in dietary vitamin K&lt;sub&gt;2&lt;/sub&gt; intake (HR=0.93, p=0.04)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex: 26% male</td>
<td>Intervention: dietary vitamin K&lt;sub&gt;2&lt;/sub&gt; and K&lt;sub&gt;1&lt;/sub&gt; intake using FFQ</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age: 49</td>
<td>Follow-up (years): 10</td>
<td></td>
</tr>
<tr>
<td>Choi et al&lt;sup&gt;100&lt;/sup&gt;</td>
<td>42</td>
<td>Healthy young volunteers</td>
<td>Design: Placebo-controlled trial</td>
<td>↑Insulin sensitivity index (p=0.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex: Male only</td>
<td>Intervention: vitamin K&lt;sub&gt;2&lt;/sub&gt; supplementation (30 mg)</td>
<td>↑Disposition index (p&lt;0.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age (median): 29</td>
<td>Follow-up (weeks): 4</td>
<td>↑cCO (p=0.01)</td>
</tr>
<tr>
<td>Asemi et al&lt;sup&gt;101&lt;/sup&gt;</td>
<td>66</td>
<td>Overweight patients with diabetes aged 40–85 years, living in Iran</td>
<td>Design: Double-blind RCT</td>
<td>↓Maximum carotid intima media thickness (p=0.02)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex: 47% female</td>
<td>Intervention: vitamin D (5 µg)</td>
<td>↓HOMA-IR (p=0.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age: 65</td>
<td>+K (90 µg) + calcium (500 mg) supplementation</td>
<td>↓HOMA-B (p=0.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Follow-up (weeks): 12</td>
<td>↑QUICKI (p=0.01)</td>
</tr>
<tr>
<td>Knapen et al&lt;sup&gt;102&lt;/sup&gt;</td>
<td>214</td>
<td>Healthy, postmenopausal women</td>
<td>Design: randomised, placebo-</td>
<td>Only in good responders (↑cCO):</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex: female only</td>
<td>controlled trial</td>
<td>↑Total and HMW adiponectin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age: 55–65</td>
<td>Intervention: vitamin K&lt;sub&gt;2&lt;/sub&gt; (MK-7) 180 µg/day or placebo</td>
<td>↓Abdominal fat mass (waist circumference and VAT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Follow-up (years): 3</td>
<td></td>
</tr>
</tbody>
</table>

Continued
### Table 1  
Continued

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Patient population</th>
<th>Study methods</th>
<th>Study findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular calcification</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Beulens et al | 564 | Healthy Dutch subjects aged 49–70 years not on HRT or contraceptives, sampled (2002–2004) from the PROSPECT-EPIC Study | Design: population-based, cross-sectional study  
**Intervention:** vitamin K₁ and K₂ (MK-4–MK-10) intake using FFQ  
Follow-up: | ↓Coronary calcification with MK intake only  
(RR=0.80 (0.65 to 0.98), p =0.03) |
| Shea et al | 388 | Asymptomatic, ambulatory community-dwelling subjects aged 60–80 years | Design: double-blind RCT  
**Intervention:** vitamin K₁ supplementation (500 µg)  
Follow-up (years): 3 | ↓CAC progression in those >85% adherent to supplementation (p=0.03) |
| Fusaro et al | 387 | Patients on haemodialysis for ≥1 year | Design: prospective observational study  
**Comparison groups:** patients with or without vitamin K₁ or vitamin K₂ (MK-4, MK-5 or MK-7) deficiency  
Follow-up (years): 3 | ↑Risk of abdominal aortic calcification with MK-4 deficiency (OR=2.8, p=0.026)  
↑Risk of iliac calcification with MK-7 deficiency (OR=1.6, p=0.042) |
| Kurnatowska et al | 42 | Non-smoking, non-dialysed Caucasians with CKD stages 3–5, stable renal function for ≥6 months and CAC ≥10 AU | Design: double-blind RCT  
**Intervention:** vitamins K₁ (MK-7, 30 µg)+D₃ (10 µg) vs D₃ (10 µg)  
Follow-up (months): 9 | ↓Change in CCA intima-media thickness in vitamin K₁ +D group (0.06±0.08 vs 0.14±0.05 mm, p=0.005)  
Nonsignificant decrease in ΔCAC score in K₁ +D group (p=0.7) |
| Ikari et al | 26 | Patients with coronary calcification and at least 1 coronary risk factor | Design: open-label, single arm  
**Intervention:** vitamin K₁ (MK-4) supplementation (45 mg)  
Follow-up (years): 1 | ↑CAC score by 14% (p=0.02) |
| Zwakenberg et al | 68 | Subjects aged >40 years with CVD, type 2 diabetes, and eGFR >30 | Design: double-blind RCT  
**Intervention:** vitamin K₁ (MK-7) supplementation (360 µg)  
Follow-up (months): 6 | No change in femoral arterial calcification on¹⁸F-NaF PET scan (p=0.06) or CT scan (p=0.18) |
| Oikonomaki et al | 102 | Adults with ESRD on haemodialysis  
Sex: not specified  
Age: 67 | Design: prospective, randomised, open-label clinical trial  
**Intervention:** vitamin K₁ supplementation (200 µg)  
Follow-up (years): 1 | No change in abdominal aortic calcification via CT-measured Agatston score |
| De Vriese et al | 132 | Chronic haemodialysis patients with non-valvular atrial fibrillation and CHA₂DS₂-VASc score ≥2  
Sex: 33% female  
Age: 80 | Design: multicentre, prospective, randomised, open-label trial  
**Intervention:** VKA vs rivaroxaban vs rivaroxaban +vitamin K₁ (2000 µg three times per week)  
Follow-up (months): 18 | No differences in change of PWV or coronary artery, thoracic aorta, or cardiac valve calcium scores at follow-up, or all-cause death, stroke or cardiovascular events between groups |
| Bartstra et al | 68 | Subjects aged >40 years with CVD, type 2 diabetes, and eGFR >30  
Sex: 24% female  
Age: 69 | Design: post-hoc analysis of double-blind RCT  
**Intervention:** vitamin K₁ (MK-7) supplementation (360 µg)  
Follow-up (months): 6 | No change in total arterial calcification, assessed by CT scan in several large arterial beds |

Continued
inversely correlated with CAC in healthy elderly individuals.\textsuperscript{91} Further, vitamin K\textsubscript{2} slowed the progression of CAC at 3-year follow-up.\textsuperscript{89} Yet, despite a significant reduction in dp-ucMGP, two recent studies failed to demonstrate a change in aortic calcification scores with vitamin K\textsubscript{2} supplementation in those on haemodialysis with or without anticoagulation.\textsuperscript{108,109} In one double-blind, placebo-controlled trial by Zwakenberg \textit{et al}, 68 patients with type 2 diabetes mellitus were randomised to receive 360 µg/day of vitamin K\textsubscript{2} (MK-7) or placebo for 6 months,\textsuperscript{110} and there was no significant difference in femoral arterial calcification measured by either \textsuperscript{18}F-sodium fluoride positron emission tomography (primary outcome) or CT scan (secondary outcome). A post-hoc analysis of this trial was recently published to investigate the effect of vitamin K\textsubscript{2} on CT-based arterial calcification mass, quantified in several large arterial beds, and there was no significant difference between placebo and supplemented groups.\textsuperscript{111} Both studies were limited by the short duration of follow-up, small sample size, low percentage of severe vitamin K deficiency and high dropout rates. Despite the evident potential of vitamin K\textsubscript{2} in modulating vascular and valvular calcification, its definitive role is yet to be fully established.

**Cardiovascular morbidity and mortality**

Table 2 summarises the studies to date of vitamin K intake and cardiovascular mortality. The first to report on dietary intake of vitamin K\textsubscript{2}, the prospective Rotterdam study recruited 4807 subjects with dietary data and no history of myocardial infarction between 1990 and 1993, and followed patients until January 2020. The authors stratified groups by quartiles of increasing vitamin K\textsubscript{2} intake, and found that the upper tertials of vitamin K\textsubscript{2} but not K\textsubscript{1} intake was inversely associated with severe aortic calcification (OR=0.48) as well as cardiovascular (relative risk (RR)=0.43) and all-cause (RR=0.74) mortality. These findings persisted after adjusting for traditional risk factors and dietary factors.\textsuperscript{112} In another prospective cohort study inclusive of women aged 49–70 years without prior CVD who were enrolled between 1993 and 1997 as part of the European Prospective EPIC cohort (mean follow-up of 8.1±1.6 years), vitamin K\textsubscript{2} but not K\textsubscript{1} intake was significantly and inversely associated with risk of incident CAD (HR=0.9 per 10 µg/day of vitamin K\textsubscript{2} intake).\textsuperscript{113} These findings were consistent with a prospective Norwegian study that followed 2987 healthy subjects for a median of 11 years and demonstrated an association between vitamin K\textsubscript{2} but not K\textsubscript{1} and reduced CAD risk (HR=0.52, 95% CI: 0.29 to 0.90). On longitudinal assessment, those who increased their intake of vitamin K\textsubscript{2} or vitamin K\textsubscript{1} had a lower risk of all-cause mortality (HR=0.57 and HR=0.55, respectively) relative to those with reduced or stable intake. These findings are in line with those of

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Patient population</th>
<th>Study methods</th>
<th>Study findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geleijnse \textit{et al}.\textsuperscript{81}</td>
<td>4807</td>
<td>Dutch subjects &gt;55 years without prior MI at baseline (1990–1993)</td>
<td>Design: prospective, population-based&lt;br&gt;Intervention: dietary vitamin K\textsubscript{1} and K\textsubscript{2} using FFQ&lt;br&gt;Follow-up (years): 7</td>
<td>↓Severe aortic calcification in mid and upper tertials of vitamin K\textsubscript{2} intake (OR=0.71 and 0.48, respectively; p&lt;0.05)</td>
</tr>
<tr>
<td>Brandenburg \textit{et al}.\textsuperscript{82}</td>
<td>99</td>
<td>Asymptomatic or mildly symptomatic patients without CKD with aortic valve PFV &gt;2 m/s</td>
<td>Design: prospective, single-centre, open-label RCT&lt;br&gt;Intervention: vitamin K\textsubscript{2} supplementation (2 mg)&lt;br&gt;Follow-up (years): 1</td>
<td>↓Progression in aortic valve calcification volume score (10% vs 22%, p=0.04)</td>
</tr>
</tbody>
</table>

Both ages and follow-up times are presented as mean years, unless otherwise specified, and rounded to the nearest whole number. All RCT study designs are placebo controlled unless otherwise specified. All provided dosages are per daily unless otherwise noted. P values <0.05 denote significance.

AU, Agtston units; CAC, coronary artery calcification; CCA, common carotid artery; CHD, coronary heart disease; cOCR, carboxylated osteocalcin; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; FFQ, Food Frequency Questionnaire; \textsuperscript{18}F-NaF PET, \textsuperscript{18}F-sodium fluoride positron emission tomography; HMW, human molecular weight; HOMA-B, homeostasis model for assessment of B-cell function; HOMA-IR, homeostasis model for assessment of insulin resistance; HRT, hormone replacement therapy; M1, myocardial infarction; MK, menaquinone; N/A, not applicable; PFV, peak flow velocity; PWM, pulse wave velocity; QUICKI, quantitative insulin sensitivity check index; RCT, randomised control trial; RR, relative risk; VAT, estimated visceral adipose tissue area; VKA, vitamin K antagonist.
patients with CKD who were followed for a median of 13.3 years as part of the National Health and Nutrition Examination Survey III registry (HR=0.78, 95% CI: 0.64 to 0.95, p=0.016).115 A recent meta-analysis concluded that higher dietary consumption of vitamin K1 and K2 is associated with a lower risk of CAD (pooled HR=0.92, 95% CI: 0.84 to 0.99 and HR=0.70, 95% CI: 0.53 to 0.93, respectively), but has no correlation with all-cause mortality, CVD mortality or stroke.6

Conclusions and future directions

This review covers the rapidly expanding evidence supporting the cardioprotective effects of vitamin K2 intake. Mediated by activated MGP, the benefits of vitamin K2 extend beyond calcification homeostasis and antagonism, and may further include preventing or slowing the progression of arterial stiffness, endothelial dysfunction, diabetes and HF. Moreover, vitamin K2 supplementation appears safe and practical, and its use can be readily investigated in randomised clinical trials. Although the data presented in this review are encouraging, most of the included studies were limited by their non-randomised design, heterogeneity in results, variable dosages and formulations of vitamin K used, small sample sizes, short duration of follow-up and restricted ability to accurately assess vitamin K intake, in turn precluding our ability to infer causality of clinical endpoints. With evidence mounting, the definitive role of vitamin K2 supplementation in delaying progression of vascular and valvular calcification remains the subject of multiple randomised clinical trials.116 117 Nonetheless, the utility of vitamin K2 and MGP in various patient populations such as those with valvular heart disease and cardiomyopathy needs to be further evaluated.

Table 2 Association of dietary vitamin K intake with coronary disease and cardiovascular mortality

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Patient population</th>
<th>Study methods</th>
<th>Study findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geleijnse et al11</td>
<td>4807</td>
<td>Dutch subjects &gt;55 years without prior MI at baseline (1990–1993)</td>
<td>Design: prospective, population-based intervention; vitamin K1 and K2 using FFQ</td>
<td>↓Cardiovascular mortality (RR=0.43 (0.24 to 0.77)) and all-cause mortality (RR=0.74 (0.59 to 0.92)) with K2 but not K1 in upper tertiles of energy-adjusted intake</td>
</tr>
<tr>
<td>Erkkilä et al113</td>
<td>40 087</td>
<td>Healthcare workers aged 40–75 years, free of CVD, stroke and cancer at baseline (1986–2000)</td>
<td>Design: prospective, population-based intervention; vitamin K1 using FFQ</td>
<td>↓Incidence of total CAD (RR=0.84, p trend=0.05)</td>
</tr>
<tr>
<td>Gast et al17</td>
<td>16 057</td>
<td>Subjects aged 49–70 years free of CVD, recruited from the European Prospective-EPIC cohort (1993–1997)</td>
<td>Design: prospective, population-based intervention; vitamin K1 and K2 (subtypes MK-7–9) using FFQ</td>
<td>↓Risk of incident CAD (HR=0.91 (0.85 to 1.00))</td>
</tr>
<tr>
<td>Juanola-Falgarona et al14</td>
<td>7216</td>
<td>Community-dwelling adults enrolled in PREDIMED trial, without baseline CVD but with either type 2 diabetes or ≥3 cardiovascular risk factors</td>
<td>Design: prospective, population-based intervention; dietary vitamin K1 and K2 (subtypes MK-7–9) using FFQ</td>
<td>↓All-cause mortality with increasing intake of vitamin K1 or K2 (HR=0.57 and HR=0.55, respectively; p&lt;0.05)</td>
</tr>
<tr>
<td>Cheung et al115</td>
<td>3401</td>
<td>Non-hospitalised participants ≥20 years of age with CKD from the NHANES III Study (1988–1994)</td>
<td>Design: prospective, population-based intervention; vitamin K1 and K2 using 24-hour dietary recall</td>
<td>↓All-cause (HR=0.85 (0.72 to 1), p=0.047) and CVD mortality (HR=0.78 (0.64 to 0.95), p=0.016)</td>
</tr>
<tr>
<td>Zwakenberg et al21</td>
<td>33 289</td>
<td>Dutch subjects aged 20–70 years without baseline CVD, diabetes or cancer recruited from the EPIC-NL cohort (1993–1997)</td>
<td>Design: prospective, population-based intervention; vitamin K1 and K2 using FFQ</td>
<td>Borderline ↓CHD mortality with higher long chain vitamin K2 intake (HR=0.86 (0.74 to 1.00), p trend=0.06) No association of vitamin K1 or K2 with CVD or all-cause mortality</td>
</tr>
<tr>
<td>Haugsgjerd et al112</td>
<td>2987</td>
<td>Healthy Norwegian subjects aged 46–49 years without baseline CAD recruited from the Hordaland Health Study (1997–1999)</td>
<td>Design: prospective, population-based intervention; vitamin K1 and K2 using FFQ</td>
<td>↓Risk of incident CAD with higher vitamin K2 but not K1 (HR=0.52, p trend=0.03), attenuated by adjusting for dietary confounders (HR=0.58, p trend=0.16)</td>
</tr>
</tbody>
</table>

Both ages and follow-up times are presented as mean years, or median years in Cheung et al115 and rounded to the nearest whole number. P values <0.05 denote significance.

CAD, coronary artery disease; CHD, coronary heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; FFQ, Food Frequency Questionnaire; MI, myocardial infarction; MK, menaquinone; NHANES III, National Health and Nutrition Examination Survey; RR, relative risk.

Hariri E, et al. Open Heart 2021;8:e001715. doi:10.1136/openhrt-2021-001715

Open Heart: first published as 10.1136/openhrt-2021-001715 on 16 November 2021. Downloaded from http://openheart.bmj.com/ on August 21, 2022 by guest. Protected by copyright.
grows commensurate the data supporting its efficacy in improving cardiac function and decelerating arterial stiffness.

Twitter Nicholas Kassis @kassisMD

Contributors EH conceived and designed the study. EH, NK, J-PI and AS collected, analysed and interpreted the data, and performed the literature review. EH, NK and J-PI drafted the manuscript and designed the tables. LS, TI, SCH, AB and SK revised the manuscript. OA designed the figures. TI, SCH and SK supervised the study. All authors have read and approved the manuscript.

Funding This study was made possible by a generous gift from Jennifer and Robert McNeil as unrestricted philanthropic support to the Heart and Vascular Institute, Cleveland Clinic.

Disclaimer The funding source had no role in the design or conduct of the study; collection, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Competing interests LS received an institutional grant from NattoPharma. PI drafted the manuscript and designed the tables. OA designed the figures. TI, SCH, AB and SK supervised the study. All authors have read and approved the manuscript.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data sharing not applicable as no datasets generated and/or analysed for this study.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Nicholas Kassis http://orcid.org/0000-0002-7975-0861
Serge C Harb http://orcid.org/0000-0002-7442-4928

REFERENCES


Cardiac risk factors and prevention


Hariri E, et al. *Open Heart* 2021;8.e001715. doi:10.1136/openhrt-2021-001715

Open Heart (first published as 10.1136/openhrt-2021-001715 on 16 November 2021) - Downloaded from http://openheart.bmj.com/ on August 21, 2022 by guest. Protected by copyright.


